Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system

Gerhard Hoffmann, Christoph Funk, Stephen Fowler, Michael B Otteneder, Alexander Breidenbach, Craig R. Rayner, Tom Chu, Eric P. Prinssen

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)

Abstract

Oseltamivir, a potent and selective inhibitor of influenza A and B virus neuraminidases, is a prodrug that is systemically converted into the active metabolite oseltamivir carboxylate. In light of reported neuropsychiatric events in influenza patients, including some taking oseltamivir, and as part of a full assessment to determine whether oseltamivir could contribute to, or exacerbate, such events, we undertook a series of nonclinical studies. In particular, we investigated (i) the distribution of oseltamivir and oseltamivir carboxylate in the central nervous system of rats after single intravenous doses of oseltamivir and oseltamivir carboxylate and oral doses of oseltamivir, (ii) the active transport of oseltamivir and oseltamivir carboxylate in vitro by transporters located in the blood-brain barrier, and (iii) the extent of local conversion of oseltamivir to oseltamivir carboxylate in brain fractions. In all experiments, results showed that the extent of partitioning of oseltamivir and especially oseltamivir carboxylate to the central nervous system was low. Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate. Apart from oseltamivir being a good substrate for the P-glycoprotein transporter, no other active transport processes were observed. The conversion of the prodrug to the active metabolite was slow and limited in human and rat brain S9 fractions. Overall, these studies indicate that the potential for oseltamivir and oseltamivir carboxylate to reach the central nervous system in high quantities is low and, together with other analyses and studies, that their involvement in neuropsychiatric events in influenza patients is unlikely.

Original languageEnglish
Pages (from-to)4753-4761
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume53
Issue number11
DOIs
Publication statusPublished - Nov 2009
Externally publishedYes

Cite this

Hoffmann, G., Funk, C., Fowler, S., Otteneder, M. B., Breidenbach, A., Rayner, C. R., ... Prinssen, E. P. (2009). Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrobial Agents and Chemotherapy, 53(11), 4753-4761. https://doi.org/10.1128/AAC.01541-08
Hoffmann, Gerhard ; Funk, Christoph ; Fowler, Stephen ; Otteneder, Michael B ; Breidenbach, Alexander ; Rayner, Craig R. ; Chu, Tom ; Prinssen, Eric P. / Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. In: Antimicrobial Agents and Chemotherapy. 2009 ; Vol. 53, No. 11. pp. 4753-4761.
@article{c378e606932b4966b7d52a5a398c9f9d,
title = "Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system",
abstract = "Oseltamivir, a potent and selective inhibitor of influenza A and B virus neuraminidases, is a prodrug that is systemically converted into the active metabolite oseltamivir carboxylate. In light of reported neuropsychiatric events in influenza patients, including some taking oseltamivir, and as part of a full assessment to determine whether oseltamivir could contribute to, or exacerbate, such events, we undertook a series of nonclinical studies. In particular, we investigated (i) the distribution of oseltamivir and oseltamivir carboxylate in the central nervous system of rats after single intravenous doses of oseltamivir and oseltamivir carboxylate and oral doses of oseltamivir, (ii) the active transport of oseltamivir and oseltamivir carboxylate in vitro by transporters located in the blood-brain barrier, and (iii) the extent of local conversion of oseltamivir to oseltamivir carboxylate in brain fractions. In all experiments, results showed that the extent of partitioning of oseltamivir and especially oseltamivir carboxylate to the central nervous system was low. Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate. Apart from oseltamivir being a good substrate for the P-glycoprotein transporter, no other active transport processes were observed. The conversion of the prodrug to the active metabolite was slow and limited in human and rat brain S9 fractions. Overall, these studies indicate that the potential for oseltamivir and oseltamivir carboxylate to reach the central nervous system in high quantities is low and, together with other analyses and studies, that their involvement in neuropsychiatric events in influenza patients is unlikely.",
author = "Gerhard Hoffmann and Christoph Funk and Stephen Fowler and Otteneder, {Michael B} and Alexander Breidenbach and Rayner, {Craig R.} and Tom Chu and Prinssen, {Eric P.}",
year = "2009",
month = "11",
doi = "10.1128/AAC.01541-08",
language = "English",
volume = "53",
pages = "4753--4761",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "American Society for Microbiology",
number = "11",

}

Hoffmann, G, Funk, C, Fowler, S, Otteneder, MB, Breidenbach, A, Rayner, CR, Chu, T & Prinssen, EP 2009, 'Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system', Antimicrobial Agents and Chemotherapy, vol. 53, no. 11, pp. 4753-4761. https://doi.org/10.1128/AAC.01541-08

Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. / Hoffmann, Gerhard; Funk, Christoph; Fowler, Stephen; Otteneder, Michael B; Breidenbach, Alexander; Rayner, Craig R.; Chu, Tom; Prinssen, Eric P.

In: Antimicrobial Agents and Chemotherapy, Vol. 53, No. 11, 11.2009, p. 4753-4761.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system

AU - Hoffmann, Gerhard

AU - Funk, Christoph

AU - Fowler, Stephen

AU - Otteneder, Michael B

AU - Breidenbach, Alexander

AU - Rayner, Craig R.

AU - Chu, Tom

AU - Prinssen, Eric P.

PY - 2009/11

Y1 - 2009/11

N2 - Oseltamivir, a potent and selective inhibitor of influenza A and B virus neuraminidases, is a prodrug that is systemically converted into the active metabolite oseltamivir carboxylate. In light of reported neuropsychiatric events in influenza patients, including some taking oseltamivir, and as part of a full assessment to determine whether oseltamivir could contribute to, or exacerbate, such events, we undertook a series of nonclinical studies. In particular, we investigated (i) the distribution of oseltamivir and oseltamivir carboxylate in the central nervous system of rats after single intravenous doses of oseltamivir and oseltamivir carboxylate and oral doses of oseltamivir, (ii) the active transport of oseltamivir and oseltamivir carboxylate in vitro by transporters located in the blood-brain barrier, and (iii) the extent of local conversion of oseltamivir to oseltamivir carboxylate in brain fractions. In all experiments, results showed that the extent of partitioning of oseltamivir and especially oseltamivir carboxylate to the central nervous system was low. Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate. Apart from oseltamivir being a good substrate for the P-glycoprotein transporter, no other active transport processes were observed. The conversion of the prodrug to the active metabolite was slow and limited in human and rat brain S9 fractions. Overall, these studies indicate that the potential for oseltamivir and oseltamivir carboxylate to reach the central nervous system in high quantities is low and, together with other analyses and studies, that their involvement in neuropsychiatric events in influenza patients is unlikely.

AB - Oseltamivir, a potent and selective inhibitor of influenza A and B virus neuraminidases, is a prodrug that is systemically converted into the active metabolite oseltamivir carboxylate. In light of reported neuropsychiatric events in influenza patients, including some taking oseltamivir, and as part of a full assessment to determine whether oseltamivir could contribute to, or exacerbate, such events, we undertook a series of nonclinical studies. In particular, we investigated (i) the distribution of oseltamivir and oseltamivir carboxylate in the central nervous system of rats after single intravenous doses of oseltamivir and oseltamivir carboxylate and oral doses of oseltamivir, (ii) the active transport of oseltamivir and oseltamivir carboxylate in vitro by transporters located in the blood-brain barrier, and (iii) the extent of local conversion of oseltamivir to oseltamivir carboxylate in brain fractions. In all experiments, results showed that the extent of partitioning of oseltamivir and especially oseltamivir carboxylate to the central nervous system was low. Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate. Apart from oseltamivir being a good substrate for the P-glycoprotein transporter, no other active transport processes were observed. The conversion of the prodrug to the active metabolite was slow and limited in human and rat brain S9 fractions. Overall, these studies indicate that the potential for oseltamivir and oseltamivir carboxylate to reach the central nervous system in high quantities is low and, together with other analyses and studies, that their involvement in neuropsychiatric events in influenza patients is unlikely.

UR - http://www.scopus.com/inward/record.url?scp=70350277967&partnerID=8YFLogxK

U2 - 10.1128/AAC.01541-08

DO - 10.1128/AAC.01541-08

M3 - Article

C2 - 19721074

AN - SCOPUS:70350277967

VL - 53

SP - 4753

EP - 4761

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 11

ER -